NASDAQ: DMRADamora Therapeutics Inc Stock
$21.96+0.70 (+3.29%)
Updated Oct 27, 2026
DMRA Price
$21.96
Fair Value Price
N/A
Market Cap
$1.36B
52 Week Low
$4.95
52 Week High
$38.33
P/E
2.93x
P/B
2.63x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$262.83M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.05
Operating Cash Flow
-$45M
Beta
1.38
Next Earnings
Nov 5, 2026
Ex-Dividend
N/A
Next Dividend
N/A
DMRA Overview
Galecto, Inc. is a clinical-stage biotechnology company developing molecules for the treatment of fibrosis, cancer, inflammation, and related diseases. Its research centers on the use of modulators proteins galectin-3 and LOXL-2. The company was founded in 2011 and is based in Boston, MA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine DMRA's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +5.11% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
DMRA
Ranked#181 of 452
Ranked#181 of 452
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $10.92 | A | |
| $366.06 | A | |
| $128.50 | A |
Be the first to know about important DMRA news, forecast changes, insider trades & much more!
DMRA News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how DMRA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
DMRA was unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
DMRA is good value based on its earnings relative to its share price (2.93x), compared to the US market average (48.65x)
P/E vs Market Valuation
DMRA is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more DMRA due diligence checks available for Premium users.
Valuation
DMRA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
2.93x
Industry
16.27x
Market
48.65x
DMRA is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
DMRA is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
DMRA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.63x
Industry
5.1x
DMRA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
DMRA's financial health
Profit margin
Revenue
$0.0
Net Income
-$31.2M
Profit Margin
0%
DMRA's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$543.6M
Liabilities
$27.6M
Debt to equity
0.05
DMRA's short-term assets ($543.59M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
DMRA's short-term assets ($543.59M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
DMRA's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
DMRA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$21.9M
Investing
$0.0
Financing
$29.5M
DMRA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
DMRA vs Biotech Stocks
Damora Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.